Immune Super IntelligenceWhere Immunology Meets Advanced AIExplore the Immune System
Therapy

Deucravacitinib

First allosteric kinase inhibitor approved in immunology: binds JH2 pseudokinase regulatory domain of TYK2 (NOT the ATP-binding active JH1 domain).

Also called: Sotyktu, TYK2 inhibitor, allosteric TYK2

Ask about Deucravacitinib See in graph Sources

In short

  1. 1What it is: a therapy in therapies and applications.
  2. 2How it connects: acts on 3 and is affected by 1 concepts — mostly 2 molecule, 1 disease, 1 trial.
  3. 3Where it sits: therapy on the 15-step immune chain.

What it does

FDA approved 2022 for moderate-severe plaque psoriasis.

Its connections at a glance

Each dot is a concept directly linked to Deucravacitinib. Colours show the kind of concept.

POETYK PSO-1TYK2PsoriasisTYK2Deucravacitinib

Learn next

Comes beforePOETYK PSO-1TrialLeads toPsoriasisDisease
Sources & evidenceloading…

Loading reviewed sources…

Graph ID I020 · concept status: established. Select any connection above to inspect evidence for that specific link.